Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : South Korea weighs more virus curbs as daily infections surge

04/07/2021 | 09:40pm EDT

SEOUL, April 8 (Reuters) - South Korea reported 700 new coronavirus cases on Thursday, its highest daily tally since early January, and the prime minister reiterated warnings that new social distancing rules would likely be needed.

The new figure compares with an average of 477 cases a day last week, according to data from the Korea Disease Control and Prevention Agency and will fuel fears the country may be facing a fourth wave of infections.

Prime Minister Chung Sye-kyun told a government meeting a new wave could disrupt South Korea's vaccination programme, which has been suffering delays as the international vaccine-sharing scheme COVAX struggles to provide promised doses on time.

South Korea said on Wednesday it would suspend providing AstraZeneca's COVID-19 vaccine to people below the age of 60 as the shot undergoes reviews in Europe.

Authorities will decide whether to resume vaccinations with the AstraZeneca shots for people under 60 this weekend, Kim Ki-nam, head of a vaccination task force, told a briefing.

South Korea approved a Johnson & Johnson shot in a bid to speed up its inoculation rollout.

Officials have said a new round of restrictions are likely to be announced by Friday. South Korea currently limits private gatherings of more than four people.

South Korea has to date reported 107,598 infections in total, with 1,758 deaths.

Over a million South Koreans have received a first shot of a coronavirus vaccine since February. (Reporting by Sangmi Cha; Editing by Edwina Gibbs, Robert Birsel)


© Reuters 2021
All news about ASTRAZENECA PLC
03:55pASTRAZENECA  : India approves Russia's Sputnik V COVID-19 vaccine
RE
12:29pTHE LATEST : CDC head warns against surging shots to Michigan
AQ
12:08pLONDON STOCK EXCHANGE : FTSE 100 ends lower as miners track lower metal prices; ..
RE
10:25aASTRAZENECA  : Argus Research Downgrades AstraZeneca to Hold From Buy
MT
09:35aASTRAZENECA  : Ireland set to restrict use of AstraZeneca vaccine -RTE
RE
09:33aAustralia Expects Big Delays to Vaccine Rollout
DJ
09:02aBulgarian PM reveals price for EU's new vaccine contract with Pfizer
RE
08:35aASTRAZENECA  : Brazil, Mexico, Philippines among those due to get Pfizer shots f..
RE
08:00aSpain expects first batch of single-dose Janssen shot within 48 hours
AQ
07:26aEUROPE ECONOMICS : Action Economics on The UK Week Ahead; COVID-19 Vaccine Rollo..
MT
More news
Financials (USD)
Sales 2021 30 893 M - -
Net income 2021 4 586 M - -
Net Debt 2021 14 367 M - -
P/E ratio 2021 27,7x
Yield 2021 2,86%
Capitalization 131 B 131 B -
EV / Sales 2021 4,71x
EV / Sales 2022 4,06x
Nbr of Employees 76 100
Free-Float 95,8%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 130,05 $
Last Close Price 99,88 $
Spread / Highest target 66,2%
Spread / Average Target 30,2%
Spread / Lowest Target -5,71%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-0.51%131 272
JOHNSON & JOHNSON2.46%424 524
ROCHE HOLDING AG0.21%288 043
PFIZER, INC.-0.57%204 161
NOVARTIS AG-3.29%197 172
MERCK & CO., INC.-6.71%193 164